Bellwyck Pharma Services has joined US-based PCI’s global network
Photo as seen on PCI Twitter showing company presence
PCI Pharma Services (PCI) has acquired Bellwyck Pharma Services, headquartered in Toronto, Canada. With 25 years of experience, Bellwyck provides primary and secondary packaging and labelling for clinical trial and commercial drug markets
The acquisition will add four GMP-compliant facilities to US-based PCI’s network in the US, Germany and Canada. With Canada and Germany ranked third and fourth in the world for total number of clinical trials, respectively, this acquisition greatly enhances the global reach of PCI’s services in key markets.
Bellwyck’s clinical and commercial supply chain solutions mirror PCI’s existing core capabilities including extensive clinical trial packaging, labelling and logistics for Phase I-IV studies as well as full-service commercial packaging. With the addition of Bellwyck, PCI will now feature 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 highly trained associates.
Jeff Sziklai, CEO of Bellwyck Pharma Service, said: “Joining forces with a global industry leader, such as PCI, is a great step forward for Bellwyck. We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customised clinical trial solutions for our clients.”
The acquisition of Bellwyck to establish a presence in Canada and Germany further underscores PCI’s global strategy. The addition will mark PCI’s third acquisition outside of the US in three years, demonstrating PCI’s continued commitment to growth, geographic expansion and serving patients across the world.